Carmen Tomoroga

Dr. Carmen Tomoroga


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2025 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Ionut LedetiIonut Ledeti
Ionut Ledeti
CTClaudia Temereancă
Claudia Temereancă
Amalia Ioana RidichieAmalia Ioana Ridichie
Amalia Ioana Ridichie
Adriana LedetiAdriana Ledeti
Adriana Ledeti
Denisa IvanDenisa Ivan
Denisa Ivan
OSOana Suciu
Oana Suciu
Sulfobutyl-ether-beta-cyclodextrin sodium salt (SBECD) is a modified cyclodextrin widely used in the pharmaceutical industry to enhance the solubility and stability of poorly water-soluble drugs. As a derivative of beta-cyclodextrin, it is produced by introducing sulfobutyl ether groups into the beta-cyclodextrin molecule, which significantly increases its water solubility and decreases its toxicity compared to unmodified cyclodextrins. This study investigates the spectral and PXR diffraction characterization of SBECD, its thermal stability profile, and decomposition mechanism using isoconversional methods. Since the simple ASTM E698 method does not provide realistic data, the Flynn–Wall–Ozawa, Friedman, and NPK methods were employed, leading to the kinetic triplet that characterizes the oxidative thermolysis of this compound.

22 November 2024 in Molecules
Verified
Journal Article
Open access
PDF file
Adriana LedetiAdriana Ledeti
Adriana Ledeti
BBBianca Baul
Bianca Baul
Amalia Ioana RidichieAmalia Ioana Ridichie
Amalia Ioana Ridichie
Denisa IvanDenisa Ivan
Denisa Ivan
Vlase TitusVlase Titus
Vlase Titus
Ionut LedetiIonut Ledeti
Ionut Ledeti
Angiotensin II receptor antagonists are tetrazole derivatives used in the treatment of high blood pressure, and are also indicated for the treatment of heart failure (NYHA class II-IV). They are used alone or in combination with other classes of antihypertensives or diuretics for the effective management of high blood pressure. In this study, we aim to evaluate the thermal stability and degradation kinetics for the principal compounds used in therapy from this class, namely telmisartan, valsartan, olmesartan medoxomil, and losartan potassium. To obtain the thermoanalytical data for the kinetic investigations, the TG and DTG curves were registered at five different heating rates (β = 2, 4, 6, 8, and 10 °C min−1). The kinetic methods used were a preliminary ASTM E698 method and two isoconversional methods: Flynn–Wall–Ozawa and Friedman. For each molecule, the results showed complex decomposition processes consisting of complex reaction sequences.

17 January 2024
Verified
Journal Article
Open access
Amalia Ioana RidichieAmalia Ioana Ridichie
Amalia Ioana Ridichie
Adriana LedetiAdriana Ledeti
Adriana Ledeti
DIDenisa Ivan
Denisa Ivan
CTCarmen Tomoroga
Carmen Tomoroga
Laura SbârceaLaura Sbârcea
Laura Sbârcea
Ionut LedetiIonut Ledeti
Ionut Ledeti
Mupirocin is a topical antibiotic widely used to treat various skin infections caused by Gram-positive and Gram-negative bacteria, being the first-line treatment in the case of an infection with methicillin-resistant Staphylococcus aureus (MRSA). Due to the unique mechanism of action, it does not possess any cross-resistance with other antibiotics, leading to its global use in different hospital departments. The main disadvantage of mupirocin is represented by its pharmacokinetic properties, leading to the main purpose of this study, namely, to fully characterize the physicochemical properties of the active pharmaceutical ingredient. Currently, it is used in different combinations with other active substances, for example metronidazole, to decrease the risk of developing resistance to mupirocin and to improve the therapeutic response. This leads to the second purpose of this study, i.e., to characterize the physico-chemical profile of metronidazole and to find out if there are any chemical interactions between the two compounds, and to establish if there is a possibility of using them in the same pharmaceutical formulation, thus increasing the compliance of the patient to the treatment.

17 March 2026 in Molecules
Verified
Journal Article
Open access
PDF file
Adriana LedetiAdriana Ledeti
Adriana Ledeti
R(Ramona Pârvănescu (Pană)
Ramona Pârvănescu (Pană)
Amalia Ioana RidichieAmalia Ioana Ridichie
Amalia Ioana Ridichie
Vlase TitusVlase Titus
Vlase Titus
OSOana Suciu
Oana Suciu
CTCristina Trandafirescu
Cristina Trandafirescu
This study presents a comparative thermal and kinetic analysis of three benzimidazole derivatives used in the pharmaceutical field: fenbendazole, mebendazole, and flubendazole. The investigations were carried out using thermoanalytical methods, including thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC), in order to evaluate thermal stability, decomposition stages, and to calculate kinetic parameters. The obtained data were processed using isoconversional methods (Ozawa–Flynn–Wall, and Friedman) and non-parametric method (NPK) to determine activation energies and degradation mechanisms. The results revealed significant differences among the three compounds regarding their thermal stability and decomposition behavior, influenced by molecular structure and aromatic substituents. Furthermore, the comparative analysis provides valuable insights for optimizing technological processes, assessing stability in pharmaceutical formulations, and expanding research on the therapeutic potential of these compounds, including in oncological studies. Overall, the study contributes to a deeper understanding of the relationship between chemical structure and thermal stability in benzimidazole derivatives.

21 August 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SASimona Ardelean
Simona Ardelean
ICIoana Ciopănoiu
Ioana Ciopănoiu
ICIoana Cuc-Hepcal
Ioana Cuc-Hepcal
ASAnda Olivia Jesamine Samoila
Anda Olivia Jesamine Samoila
CMCorina Morodan
Corina Morodan
CRISTINA ADRIANA DEHELEANCRISTINA ADRIANA DEHELEAN
CRISTINA ADRIANA DEHELEAN
Most active pharmaceutical ingredients (APIs) reach their target by passive systemic distribution, so the dose required for efficacy at the lesion is set by what healthy tissue can tolerate; conventional dosage forms consequently produce pharmacokinetic profiles that oscillate between toxic peaks and sub-therapeutic troughs. Nanoparticulate carriers (liposomes, lipid nanoparticles, polymeric and inorganic systems, and biomimetic carriers) and hydrogels (natural, synthetic, supramolecular, and microgel-assembled) have emerged as the dominant strategies to address this, increasingly combined as hybrid nanoparticle–hydrogel constructs in which the gel provides locoregional retention and the nanoparticles provide cargo protection, intracellular delivery and stimuli responsiveness. Stimuli-responsive chemistries (pH, redox, enzyme, ROS, hypoxia, temperature, light, magnetic, ultrasound, glucose, and multi-stimuli logic) translate the molecular signatures of a disease into spatiotemporally controlled cargo release. This narrative review consolidates the state of the art (prioritizing 2022–2026) and departs from the conventional carrier-type survey in one respect: the literature is read along an explicit chain—disease cue, sensing chemistry, carrier architecture, release mechanism and kinetics, administration route, and clinical readiness—which exposes a variable that classification by carrier type conceals. Across all three material classes, what governs release behavior is not primarily the carrier chemistry but the identity of the released species (dissolved drug, drug from an embedded nanoparticle, an intact nanoparticle, and a matrix fragment) and the transport step that limits it. This is why power-law exponent analysis developed for dissolved drug fits particulate release poorly, why statistical goodness-of-fit cannot by itself establish a release mechanism, and why carrier class predicts clinical readiness less well than administration route and regulatory product type. Translational hurdles—CMC complexity, regulatory fragmentation, anti-PEG immunogenicity, and the structural mismatch between preclinical promise and clinical efficacy—are critically appraised in light of previously reported <1% delivery efficiency analysis. This review identifies converging strategies that could move stimuli-responsive controlled release from an aspirational outcome to a routine clinical reality.

8 December 2025 in Journal of Thermal Analysis and Calorimetry
Verified
Journal Article
Closed access
PDF file
Ionut LedetiIonut Ledeti
Ionut Ledeti
CBCosmina Bengescu
Cosmina Bengescu
Adriana LedetiAdriana Ledeti
Adriana Ledeti
GVGabriela Vlase
Gabriela Vlase
Vlase TitusVlase Titus
Vlase Titus
DIDenisa Ivan
Denisa Ivan